Ditchcarbon
  • Customers
  1. Organizations
  2. Viatris
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 13 days ago

Viatris

Company website

Viatris Inc., a global healthcare company formed through the merger of Mylan and Upjohn, is headquartered in the United States. Established in 2020, Viatris operates in over 165 countries, focusing on the pharmaceutical industry with a commitment to providing access to high-quality medicines. The company’s core business areas include generic and specialty pharmaceuticals, biosimilars, and over-the-counter products. Viatris is renowned for its extensive portfolio, which features a diverse range of medications that address various health conditions, including chronic diseases and infectious diseases. Its unique approach combines a broad product offering with a strong emphasis on patient access and affordability. With a significant market presence, Viatris has achieved notable milestones, including the successful integration of its legacy companies and a commitment to sustainable healthcare solutions.

DitchCarbon Score

How does Viatris's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

41

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Viatris's score of 41 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.

65%

Let us know if this data was useful to you

Viatris's reported carbon emissions

In 2024, Viatris reported total carbon emissions of approximately 355,000,000 kg CO2e, with Scope 1 emissions accounting for about 95,000,000 kg CO2e. In the previous year, 2023, the company disclosed emissions of approximately 355,000,000 kg CO2e globally, with Scope 1 emissions at about 96,000,000 kg CO2e. Notably, Viatris has set ambitious targets to reduce its greenhouse gas emissions. The company aims to achieve a 42% reduction in absolute Scope 1 and 2 emissions by 2030, using a 2020 baseline. Additionally, it has committed to a 25% reduction in absolute Scope 3 emissions, which encompass purchased goods and services, capital goods, and upstream transportation and distribution, also by 2030. In the UK, Viatris reported Scope 2 emissions of approximately 295,000 kg CO2e in 2023, alongside Scope 3 emissions of about 4,105,000 kg CO2e. The company has also pledged to support a net-zero ambition by 2050 for its UK operations. Viatris's climate commitments are aligned with the Science Based Targets initiative (SBTi), ensuring that their targets are consistent with the reductions necessary to limit global warming to 1.5°C. Overall, Viatris is actively working towards significant emissions reductions while maintaining transparency in its sustainability efforts.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2015201620172018201920202021202220232024
Scope 1
299,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
Scope 2
354,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
-
-
-
-
Scope 3
-
-
-
-
-
-
-
-
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Viatris's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Viatris is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Viatris is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 10 hours ago

Shasun Pharmaceuticals Limited

IN
•
Pharmaceutical Preparation Manufacturing
Updated 28 days ago

Genentech

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Allergan

US
•
Pharmaceutical Preparation Manufacturing
Updated about 14 hours ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated about 7 hours ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated about 12 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250821.7
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy